A Phase II Trial of Everolimus for Cancer Patients With Inactivating Mutations in TSC1 or TSC2 or Activating MTOR Mutations
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Everolimus (Primary)
- Indications Tuberous sclerosis
- Focus Therapeutic Use
- 28 Feb 2018 Planned primary completion date changed from 1 May 2018 to 1 Dec 2018.
- 10 Jun 2017 Biomarkers information updated
- 08 Sep 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.